Physician

Pablo C Reyes, MD

According to 2025 Medicare claims, Pablo Reyes, MD (NPI: 1891729786) practices hematology/oncology in the Orlando-Kissimmee-Sanford, FL market, with the plurality of this provider's patient population coming from Lake, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32159-6812.

Reyes' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,314 traditional Medicare patients, billed 318,334 HCPCS/CPT codes, and received $3,888,164 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,636 prescription claims across 318 beneficiaries totaling $4,592,899 in drug costs, led by Revlimid (Lenalidomide). DME data shows 17 claims. Open Payments data shows 38 records totaling $832. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,901,496 to $4,592,899. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $6,981 to $2,599.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,619	561,929	$3,766,318
2016	1,822	583,516	$3,818,482
2017	1,808	540,330	$4,244,894
2018	1,773	679,600	$5,543,582
2019	1,799	644,878	$5,091,487
2020	1,667	566,370	$5,442,746
2021	1,674	603,315	$5,729,669
2022	1,527	536,479	$4,867,802
2023	1,420	379,807	$4,110,413
2024	1,314	318,334	$3,888,164

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	290	1,406	$1,901,496
2016	308	1,417	$2,120,400
2017	332	1,642	$2,167,357
2018	372	1,683	$2,672,081
2019	364	1,670	$3,322,418
2020	347	1,669	$3,585,532
2021	323	1,497	$3,894,470
2022	308	1,442	$4,155,964
2023	294	1,553	$4,186,262
2024	318	1,636	$4,592,899

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	14	167	$33,386
2016	30	154	$34,312
2017	16	67	$3,235
2018	14	75	$3,767
2019	15	102	$7,672
2020	11	51	$2,136
2021	N/R	46	$4,507
2022	N/R	38	$2,255
2023	N/R	11	$1,300
2024	N/R	17	$1,782

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	694	1,180	$98
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	531	682	$61
96372	Injection of drug or substance under skin or into muscle	403	1,586	$10
36415	Insertion of needle into vein for collection of blood sample	878	2,914	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	764	2,850	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	123	3,444	$2,131,674
Imbruvica	Ibrutinib	64	1,836	$843,906
Jakafi	Ruxolitinib Phosphate	20	600	$341,737
Ibrance	Palbociclib	13	364	$211,923
Zejula	Niraparib Tosylate	11	330	$202,609

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	N/R	17	$1,782

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	38	$832	Celgene Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Pablo C. Reyes, MD?

Tedicare shows public-source Medicare data for Pablo C. Reyes, MD (NPI 1891729786), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Pablo C. Reyes, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Pablo C. Reyes, MD?

Pablo C. Reyes, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Pablo C. Reyes, MD have Open Payments data?

Pablo C. Reyes, MD has 38 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.